DK1255537T3 - Farnesylproteintransferasehæmmere til behandling af brystcancer - Google Patents
Farnesylproteintransferasehæmmere til behandling af brystcancerInfo
- Publication number
- DK1255537T3 DK1255537T3 DK01905717T DK01905717T DK1255537T3 DK 1255537 T3 DK1255537 T3 DK 1255537T3 DK 01905717 T DK01905717 T DK 01905717T DK 01905717 T DK01905717 T DK 01905717T DK 1255537 T3 DK1255537 T3 DK 1255537T3
- Authority
- DK
- Denmark
- Prior art keywords
- breast cancer
- protein transferase
- treatment
- transferase inhibitors
- farnesyl protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200373 | 2000-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1255537T3 true DK1255537T3 (da) | 2006-08-21 |
Family
ID=8170976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01905717T DK1255537T3 (da) | 2000-02-04 | 2001-02-01 | Farnesylproteintransferasehæmmere til behandling af brystcancer |
Country Status (13)
Country | Link |
---|---|
US (4) | US20030027839A1 (de) |
EP (1) | EP1255537B1 (de) |
JP (1) | JP5491681B2 (de) |
AT (1) | ATE323474T1 (de) |
AU (1) | AU2001233726A1 (de) |
CA (1) | CA2396865C (de) |
CY (1) | CY1105477T1 (de) |
DE (1) | DE60118889T2 (de) |
DK (1) | DK1255537T3 (de) |
ES (1) | ES2262626T3 (de) |
PT (1) | PT1255537E (de) |
SI (1) | SI1255537T1 (de) |
WO (1) | WO2001056552A2 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
US20040110769A1 (en) * | 2001-02-15 | 2004-06-10 | End David William | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
CN101181269A (zh) * | 2001-11-30 | 2008-05-21 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
US7102251B2 (en) * | 2003-08-22 | 2006-09-05 | Distributed Power, Inc. | Bi-directional multi-port inverter with high frequency link transformer |
EP1680118A1 (de) * | 2003-11-06 | 2006-07-19 | Schering Corporation | Kombination aus einem farnesyl-transferase-hemmer mit einem antihormonellen mittel zur behandlung von brustkrebs |
KR20070001922A (ko) | 2003-12-12 | 2007-01-04 | 와이어쓰 | 심장혈관질환 치료에 유용한 퀴놀린 |
US20050277629A1 (en) * | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
EP1732549A4 (de) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | Verfahren zur behandlung von synucleinopathien |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
EP2545919A1 (de) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Behandlung von Synucleinopathien |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
MX2011005096A (es) * | 2008-11-13 | 2011-11-18 | Link Medicine Corp | Derivados de azaquinolinona y usos de los mismos. |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2288195B1 (de) * | 2009-08-20 | 2019-10-23 | Samsung Electronics Co., Ltd. | Verfahren und Vorrichtung zum Betreiben einer Basisstation in einem drahtlosen Kommunikationssystem |
WO2014062667A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
US9303015B2 (en) | 2012-10-16 | 2016-04-05 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORγt |
HUE035335T2 (en) | 2012-10-16 | 2018-05-02 | Janssen Pharmaceutica Nv | ROR-gamma-T methylene-linked quinolinyl modulators |
CA2926339A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of roryt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
TWI710642B (zh) | 2015-08-17 | 2020-11-21 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症病患之方法 |
CA3042747A1 (en) | 2016-11-03 | 2018-05-11 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021701A1 (en) * | 1995-12-08 | 1997-06-19 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US5994364A (en) * | 1996-09-13 | 1999-11-30 | Schering Corporation | Tricyclic antitumor farnesyl protein transferase inhibitors |
TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
CA2288140C (en) * | 1997-04-25 | 2007-04-03 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
US5925639A (en) * | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
US5852034A (en) * | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
US6410534B1 (en) * | 1998-07-02 | 2002-06-25 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU762423B2 (en) * | 1998-07-06 | 2003-06-26 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties |
EP1107962B1 (de) * | 1998-08-27 | 2005-02-23 | Pfizer Products Inc. | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
DE69907964T2 (de) * | 1998-12-23 | 2004-02-19 | Janssen Pharmaceutica N.V. | 1,2-annelierte chinolinderivate |
AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
US6838467B2 (en) * | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
US20030212008A1 (en) * | 2000-02-29 | 2003-11-13 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
US20020022633A1 (en) * | 2000-06-30 | 2002-02-21 | Williams Theresa M. | Inhibitors of prenyl-protein transferase |
-
2001
- 2001-02-01 DK DK01905717T patent/DK1255537T3/da active
- 2001-02-01 SI SI200130572T patent/SI1255537T1/sl unknown
- 2001-02-01 AU AU2001233726A patent/AU2001233726A1/en not_active Abandoned
- 2001-02-01 DE DE60118889T patent/DE60118889T2/de not_active Expired - Lifetime
- 2001-02-01 EP EP01905717A patent/EP1255537B1/de not_active Expired - Lifetime
- 2001-02-01 JP JP2001556244A patent/JP5491681B2/ja not_active Expired - Lifetime
- 2001-02-01 AT AT01905717T patent/ATE323474T1/de active
- 2001-02-01 ES ES01905717T patent/ES2262626T3/es not_active Expired - Lifetime
- 2001-02-01 CA CA002396865A patent/CA2396865C/en not_active Expired - Lifetime
- 2001-02-01 PT PT01905717T patent/PT1255537E/pt unknown
- 2001-02-01 US US10/203,083 patent/US20030027839A1/en not_active Abandoned
- 2001-02-01 WO PCT/EP2001/001032 patent/WO2001056552A2/en active IP Right Grant
-
2004
- 2004-04-06 US US10/818,767 patent/US20040192726A1/en not_active Abandoned
-
2006
- 2006-07-18 CY CY20061100995T patent/CY1105477T1/el unknown
-
2008
- 2008-09-16 US US12/211,705 patent/US20090018164A1/en not_active Abandoned
-
2011
- 2011-01-06 US US12/985,579 patent/US20110098318A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2262626T3 (es) | 2006-12-01 |
JP2003521509A (ja) | 2003-07-15 |
DE60118889T2 (de) | 2006-11-30 |
EP1255537A2 (de) | 2002-11-13 |
SI1255537T1 (sl) | 2006-10-31 |
DE60118889D1 (de) | 2006-05-24 |
JP5491681B2 (ja) | 2014-05-14 |
AU2001233726A1 (en) | 2001-08-14 |
WO2001056552A3 (en) | 2002-04-25 |
US20040192726A1 (en) | 2004-09-30 |
CA2396865A1 (en) | 2001-08-09 |
ATE323474T1 (de) | 2006-05-15 |
PT1255537E (pt) | 2006-09-29 |
CY1105477T1 (el) | 2010-04-28 |
US20110098318A1 (en) | 2011-04-28 |
US20030027839A1 (en) | 2003-02-06 |
EP1255537B1 (de) | 2006-04-19 |
CA2396865C (en) | 2009-04-14 |
US20090018164A1 (en) | 2009-01-15 |
WO2001056552A2 (en) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1255537T3 (da) | Farnesylproteintransferasehæmmere til behandling af brystcancer | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
DK1648905T3 (da) | Inhibitorer for thienopyridin- og furopyridinkinase | |
ATE375794T1 (de) | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
DE60014873D1 (de) | Synergistische zusammensetzungen zur krebsbehandlung | |
BRPI0417708A (pt) | derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases | |
DK1272188T3 (da) | Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer | |
GB0112348D0 (en) | Compounds | |
DK1339407T3 (da) | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom | |
BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
DK1315506T3 (da) | Phospholipidderivater af valproinsyre og blandinger deraf | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
DE60329326D1 (de) | Tace inhibitoren | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
MXPA03005374A (es) | Carbazoles antitumorales. | |
UY26911A1 (es) | Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa | |
ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
ATE480260T1 (de) | Stabile dosierungsform von phenylalanin-derivaten | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |